Close

BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

Go back to BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy

August 5, 2016 10:46 AM EDT

Jefferies reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $120.00 (from $116.00), following the company's 2Q earnings report.

Analyst Eun Yang commented, "Higher 2Q revenue on higher Vimizim & Kuvan sales. With Naglazyme, Kuvan & Vimizim sales running... More

BioMarin Pharma's (BMRN) Q2 Revenue Tops Views

August 4, 2016 4:08 PM EDT

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.

GUIDANCE:

BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion,... More